| Title: |
Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections |
| Authors: |
Cojutti, Pier Giorgio; Gatti, Milo; Tedeschi, Sara; Zamparini, Eleonora; Meschiari, Marianna; Danzi, Maria; Menegotto, Giacomo; Cotrufo, Marco; Soavi, Laura; Chiari, Erika; Ripa, Marco; Mazzitelli, Maria; Crapis, Massimo; Cattelan, Annamaria; Parruti, Giustino; Russo, Alessandro; Zammarchi, Lorenzo; Tascini, Carlo; Viale, Pierluigi; Pea, Federico |
| Contributors: |
Cojutti, Pier Giorgio; Gatti, Milo; Tedeschi, Sara; Zamparini, Eleonora; Meschiari, Marianna; Danzi, Maria; Menegotto, Giacomo; Cotrufo, Marco; Soavi, Laura; Chiari, Erika; Ripa, Marco; Mazzitelli, Maria; Crapis, Massimo; Cattelan, Annamaria; Parruti, Giustino; Russo, Alessandro; Zammarchi, Lorenzo; Tascini, Carlo; Viale, Pierluigi; Pea, Federico |
| Publication Year: |
2025 |
| Collection: |
IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| Subject Terms: |
dalbavancin; long-term treatment; model-informed precision dosing; therapeutic drug monitoring |
| Description: |
A hub and spoke model for optimizing long-term treatment of chronic staphylococcal infections with dalbavancin based on therapeutic drug monitoring (TDM)-guided expert clinical pharmacological advice (ECPA) was implemented. This multicentric retrospective cohort study included patients receiving dalbavancin monotherapy lasting >6 weeks at different spoke hospitals having treatment optimized by means of a TDM-guided ECPA program at a hub hospital. Optimal pharmacokinetic/pharmacodynamic target against staphylococci with an MIC up to 0.125 mg/L was defined as dalbavancin concentrations >8.04 mg/L. Patients received dalbavancin therapy for curative (curative group) or suppressive (suppressive group) purposes. Clinical outcome was assessed by means of repeated ambulatory visits. A total of 12 spoke hospitals applied for 414 TDM-based ECPA for 101 patients, of whom 64.4% (65/101) were treated for curative and 35.6% (36/101) were for suppressive purposes. In the curative and suppressive groups, TDM-based ECPA optimized treatment for up to 14 and 28 months, respectively, and ensured median optimal exposure of 95.7% and 100%, respectively. In the curative group, having |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/39992102; info:eu-repo/semantics/altIdentifier/wos/WOS:001457512900018; volume:69; issue:4; firstpage:1; lastpage:13; numberofpages:13; journal:ANTIMICROBIAL AGENTS AND CHEMOTHERAPY; https://hdl.handle.net/11585/1006374 |
| DOI: |
10.1128/aac.01830-24 |
| Availability: |
https://hdl.handle.net/11585/1006374; https://doi.org/10.1128/aac.01830-24; https://journals.asm.org/doi/10.1128/aac.01830-24 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.E2708FA1 |
| Database: |
BASE |